S&P 500 7,628.29 â–ŧ 57.85 (-0.75%) DOW 52,759.94 â–ŧ 425.96 (-0.80%) NASDAQ 26,096.35 â–ŧ 274.54 (-1.04%) US Markets Closed â€ĸ 06:22 PM ET

CYCN

Cyclerion Therapeutics, Inc.

Price Chart

No historical data available

Latest Quote

$3.90

+0.22 (+5.98%)
Current Price
Previous Close $3.68
Open $3.66
Day High $4.00
Day Low $3.66
Volume 68,295
Fetched: 2026-09-01T16:32:02
Stock Information
Shares Outstanding 4.68M
Cash Equivalents $1.39M
Revenue $1.90M
Net Income $-6.71M
Sector Healthcare
Industry Biotechnology
Market Cap $18.26M
EPS (TTM) $-1.66
Exchange NCM
🌐 Visit Website
Recent Price History
No history data available. Data will be fetched automatically.
About Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

📰 Latest News
No news articles available at the moment. Check back later for updates on CYCN.
Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $2,074,000 $2,000,000 $0 $297,000
Operating Revenue $2,074,000 $2,000,000 $0 $297,000
Expenses
Total Expenses $7,047,000 $5,628,000 $9,647,000 $18,837,000
Other Income Expense $1,317,000 $363,000 $-3,304,000 -
Net Non Operating Interest Income Expense $128,000 $208,000 $358,000 $294,000
Operating Expense $7,047,000 $5,628,000 $9,647,000 $18,837,000
General And Administrative Expense $6,088,000 $5,342,000 $8,132,000 $12,858,000
Other Non Operating Income Expenses - $363,000 - -
Total Other Finance Cost - - - $-294,000
Other Operating Expenses - - - $-1,328,000
Interest Expense - - - -
Interest Expense Non Operating - - - -
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-3,528,000 $-3,057,000 $-12,593,000 $-18,246,000
Net Interest Income $128,000 $208,000 $358,000 $294,000
Interest Income $128,000 $208,000 $358,000 $294,000
Normalized Income $-4,845,000 $-3,420,000 $-9,289,000 $-18,246,000
Net Income From Continuing And Discontinued Operation $-3,528,000 $-3,057,000 $-5,263,000 $-44,078,000
Total Operating Income As Reported $-4,973,000 $-3,628,000 $-12,951,000 $-18,540,000
Net Income Common Stockholders $-3,528,000 $-3,057,000 $-5,263,000 $-44,078,000
Net Income $-3,528,000 $-3,057,000 $-5,263,000 $-44,078,000
Net Income Including Noncontrolling Interests $-3,528,000 $-3,057,000 $-5,263,000 $-44,078,000
Net Income Continuous Operations $-3,528,000 $-3,057,000 $-12,593,000 $-18,246,000
Pretax Income $-3,528,000 $-3,057,000 $-12,593,000 $-18,246,000
Special Income Charges $1,317,000 $363,000 $-3,304,000 $0
Interest Income Non Operating $128,000 $208,000 $358,000 $294,000
Operating Income $-4,973,000 $-3,628,000 $-9,647,000 $-18,540,000
Net Income Discontinuous Operations - $0 $7,330,000 $-25,832,000
Per Share
Diluted EPS $-1.11 $-1.21 $-2.25 $-20.28
Basic EPS $-1.11 $-1.21 $-2.25 $-20.28
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-6,290,000 $-3,991,000 $-6,343,000 $-18,475,000
Total Unusual Items $1,317,000 $363,000 $-3,304,000 $0
Total Unusual Items Excluding Goodwill $1,317,000 $363,000 $-3,304,000 $0
EBITDA (Bullshit earnings) $-4,973,000 $-3,628,000 $-9,647,000 $-18,475,000
EBIT $-4,973,000 $-3,628,000 $-9,647,000 $-18,540,000
Diluted Average Shares $3,181,000 $2,518,000 $2,338,000 $2,173,000
Basic Average Shares $3,181,000 $2,518,000 $2,338,000 $2,173,000
Diluted NI Availto Com Stockholders $-3,528,000 $-3,057,000 $-5,263,000 $-44,078,000
Other Special Charges $-1,317,000 $-363,000 - -
Research And Development $959,000 $286,000 $1,515,000 $5,979,000
Selling General And Administration $6,088,000 $5,342,000 $8,132,000 $12,858,000
Other Gand A $6,088,000 $5,342,000 $8,132,000 $12,858,000
Impairment Of Capital Assets - $0 $3,304,000 $0
Reconciled Depreciation - - $0 $65,000
Fetched: 2026-08-28
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $9,085,000 $8,850,000 $11,288,000 $10,452,000
Total Assets $9,985,000 $9,575,000 $13,374,000 $18,079,000
Total Non Current Assets $5,350,000 $5,350,000 $5,350,000 $3,259,000
Current Assets $4,635,000 $4,225,000 $8,024,000 $14,820,000
Other Current Assets $11,000 $16,000 $11,000 $537,000
Prepaid Assets $384,000 $421,000 $442,000 $805,000
Receivables $1,000,000 $556,000 $0 $96,000
Accounts Receivable $1,000,000 $556,000 $0 $96,000
Cash Cash Equivalents And Short Term Investments $3,240,000 $3,232,000 $7,571,000 $13,382,000
Cash And Cash Equivalents $3,240,000 $3,232,000 $7,571,000 $13,382,000
Other Non Current Assets - - - $2,041,000
Debt
Total Debt - - - -
Long Term Debt And Capital Lease Obligation - - - -
Liabilities
Total Liabilities Net Minority Interest $900,000 $725,000 $2,086,000 $7,627,000
Total Non Current Liabilities Net Minority Interest $0 $0 $0 $0
Current Liabilities $900,000 $725,000 $2,086,000 $7,627,000
Other Current Liabilities $38,000 $30,000 $113,000 $68,000
Payables And Accrued Expenses $849,000 $662,000 $1,973,000 $6,326,000
Payables $508,000 $390,000 $1,198,000 $2,970,000
Accounts Payable $508,000 $390,000 $1,198,000 $2,970,000
Current Notes Payable - - - -
Equity
Common Stock Equity $9,085,000 $8,850,000 $11,288,000 $10,452,000
Total Equity Gross Minority Interest $9,085,000 $8,850,000 $11,288,000 $10,452,000
Stockholders Equity $9,085,000 $8,850,000 $11,288,000 $10,452,000
Retained Earnings $-271,020,000 $-267,492,000 $-264,417,000 $-259,154,000
Gains Losses Not Affecting Retained Earnings - $0 $-12,000 $-20,000
Other Equity Adjustments - - $-12,000 $-20,000
Other
Ordinary Shares Number $3,821,236 $2,545,922 $2,474,159 $2,175,936
Share Issued $3,821,236 $2,545,922 $2,474,159 $2,175,936
Tangible Book Value $9,085,000 $8,850,000 $11,288,000 $10,452,000
Invested Capital $9,085,000 $8,850,000 $11,288,000 $10,452,000
Working Capital $3,735,000 $3,500,000 $5,938,000 $7,193,000
Total Capitalization $9,085,000 $8,850,000 $11,288,000 $10,452,000
Additional Paid In Capital $280,105,000 $276,342,000 $275,717,000 $269,626,000
Capital Stock $0 $0 $0 $0
Common Stock $0 $0 $0 $0
Preferred Stock $0 $0 $0 $0
Pensionand Other Post Retirement Benefit Plans Current $13,000 $33,000 $0 $1,233,000
Current Accrued Expenses $341,000 $272,000 $775,000 $3,356,000
Investments And Advances $5,350,000 $5,350,000 $5,350,000 $0
Other Investments $5,350,000 $5,350,000 $5,350,000 $0
Net PPE - $0 $0 $1,218,000
Accumulated Depreciation - $-126,000 $-126,000 $-2,181,000
Gross PPE - $126,000 $126,000 $3,399,000
Machinery Furniture Equipment - $126,000 $126,000 $2,181,000
Treasury Shares Number - - $170,937 -
Other Properties - - - $1,218,000
Capital Lease Obligations - - - -
Long Term Capital Lease Obligation - - - -
Current Capital Lease Obligation - - - -
Leases - - - -
Properties - - - -
Fetched: 2026-08-28
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-3,314,000 $-4,333,000 $-21,245,000 $-40,611,000
Operating Activities
Operating Cash Flow $-3,314,000 $-4,333,000 $-21,245,000 $-40,611,000
Cash Flow From Continuing Operating Activities $-3,314,000 $-4,333,000 $-21,245,000 $-40,611,000
Cash From Discontinued Operating Activities - - $-15,752,000 $0
Operating Gains Losses - - - -
Investing Activities
Investing Cash Flow - $0 $10,402,000 $0
Cash From Discontinued Investing Activities - $0 $10,402,000 $0
Cash Flow From Continuing Investing Activities - - - $0
Capital Expenditure - - - -
Financing Activities
Repurchase Of Capital Stock $-130,000 $0 - -
Issuance Of Capital Stock $1,375,000 $0 - $0
Financing Cash Flow $3,322,000 $0 $5,024,000 $29,000
Cash Flow From Continuing Financing Activities $3,322,000 $0 $5,024,000 $29,000
Net Other Financing Charges $2,077,000 - - -
Net Common Stock Issuance $1,245,000 $0 - $0
Common Stock Issuance $1,375,000 $0 - $0
Other
End Cash Position $3,240,000 $3,232,000 $7,571,000 $13,382,000
Beginning Cash Position $3,232,000 $7,571,000 $13,382,000 $53,961,000
Effect Of Exchange Rate Changes $0 $-6,000 $8,000 $3,000
Changes In Cash $8,000 $-4,333,000 $-5,819,000 $-40,582,000
Common Stock Payments $-130,000 $0 - -
Change In Working Capital $-227,000 $-1,538,000 $-4,601,000 $-2,850,000
Change In Other Current Assets $5,000 $-5,000 $481,000 $481,000
Change In Payables And Accrued Expense $175,000 $-998,000 $-5,541,000 $-3,458,000
Change In Accrued Expense $57,000 $-553,000 $-3,769,000 $-4,600,000
Change In Payable $118,000 $-445,000 $-1,772,000 $1,142,000
Change In Account Payable $118,000 $-445,000 $-1,772,000 $1,142,000
Change In Prepaid Assets $37,000 $21,000 $363,000 $123,000
Change In Receivables $-444,000 $-556,000 $96,000 $4,000
Changes In Account Receivables $-444,000 $-556,000 $96,000 $4,000
Stock Based Compensation $441,000 $625,000 $1,067,000 $6,252,000
Net Income From Continuing Operations $-3,528,000 $-3,057,000 $-5,263,000 $-44,078,000
Proceeds From Stock Option Exercised - $0 $5,024,000 $29,000
Other Non Cash Items - $-363,000 $-15,752,000 -
Asset Impairment Charge - $0 $3,304,000 $0
Depreciation Amortization Depletion - - $0 $65,000
Depreciation And Amortization - - $0 $65,000
Net PPE Purchase And Sale - - - $0
Sale Of PPE - - - $0
Purchase Of PPE - - - $0
Change In Other Current Liabilities - - - $0
Gain Loss On Sale Of PPE - - - $0
Issuance Of Debt - - - -
Net Issuance Payments Of Debt - - - -
Net Short Term Debt Issuance - - - -
Short Term Debt Issuance - - - -
Fetched: 2026-08-28